San Diego, California, USA, April 6, 2026
FDA Engagement Signals Registrational Pathway Progress
In a key development for oncolytic immunotherapy, Oncolytics Biotech Inc. has announced a scheduled Type C meeting with the U.S. FDA to discuss a potential registrational pathway for pelareorep in anal cancer. The meeting, set for April 16, 2026, will focus on aligning with regulators on a single-arm pivotal trial design targeting patients with squamous cell anal carcinoma (SCAC) who have progressed after first-line checkpoint inhibitor and chemotherapy treatments. This patient population represents a high unmet medical need, as there are currently no approved therapies available in later-line settings.
The company aims to evaluate objective response rate (ORR) as the primary endpoint in a study expected to enroll approximately 60–70 patients, potentially supporting full regulatory approval. This regulatory engagement marks a crucial step in accelerating pelareorep’s development and highlights its promise as a next-generation immunotherapeutic agent.
Strong Clinical Data Support Advancement
Pelareorep has already demonstrated encouraging clinical efficacy in combination with checkpoint inhibitors, particularly in late-line SCAC patients. Data from the GOBLET study (Cohort 4) showed an objective response rate of approximately 30%, significantly outperforming real-world response rates of 10–14% in similar patient populations. Additionally, the therapy achieved a median duration of response of 17 months, nearly double the 9.5 months observed with existing treatment approaches, indicating durable anti-tumor activity.
Advertisement
Pelareorep’s mechanism of action involves activating innate immune pathways and converting “cold tumors” into “hot tumors”, thereby enhancing the effectiveness of immune checkpoint inhibitors. This ability to modulate the tumor microenvironment positions pelareorep as a valuable backbone therapy in combination regimens, particularly in cancers that are resistant to conventional immunotherapies.
Addressing Unmet Needs in Rare Cancer Indications
Squamous cell anal carcinoma is a rare but increasingly prevalent cancer, with approximately 54,000 cases globally each year, and limited treatment options in advanced stages. Following progression on first-line therapies, patients face poor clinical outcomes and lack of effective alternatives, underscoring the urgency for innovative therapies. Oncolytics’ strategy to pursue a single-arm registrational trial reflects a growing trend in oncology to accelerate drug approvals in rare and high-need indications, where traditional randomized trials may be less feasible.
The potential approval pathway for pelareorep could significantly reduce development timelines while delivering meaningful clinical benefits to patients. Furthermore, the global anal cancer treatment market is projected to reach $2.3 billion by 2035, indicating both clinical and commercial significance of this therapeutic area.
Expanding Role of Oncolytic Immunotherapies
Pelareorep is part of a new class of oncolytic virus-based immunotherapies, designed to selectively infect cancer cells and stimulate anti-tumor immune responses. The therapy has shown broad clinical potential across multiple cancer types, including pancreatic, breast, colorectal, and gastrointestinal cancers, and has received FDA Fast Track designation in certain indications. By combining viral immunotherapy with checkpoint inhibitors, Oncolytics aims to enhance treatment efficacy and overcome resistance mechanisms, a major challenge in modern oncology.
The upcoming FDA meeting will be instrumental in defining the clinical and regulatory roadmap, potentially paving the way for pelareorep to become a first-in-class therapy for anal cancer. As the oncology field continues to evolve toward combination and immune-based therapies, pelareorep represents a promising innovation with the potential to transform treatment outcomes for patients with advanced cancers.
Source: Oncolytics Biotech press release
